Luseogliflozin for the treatment of type 2 diabetes.
INTRODUCTION
Sodium glucose cotransporter 2 (SGLT2) inhibitors are expected to provide adequate glycemic control, and be safe and well tolerated, for treating type 2 diabetes mellitus (T2DM). Luseogliflozin is a highly selective SGLT2 inhibitor that was recently approved for marketing and launched in Japan to treat T2DM.


AREAS COVERED
This review summarizes the published data regarding the mechanism of action, clinical efficacy, and safety of luseogliflozin for treating T2DM. Other potential benefits of luseogliflozin, including lowering body weight and blood pressure, beyond its glucose-lowering effects are also discussed.


EXPERT OPINION
Luseogliflozin lowers plasma glucose concentration and body weight, and has beneficial effects on other clinically relevant parameters, including blood pressure and uric acid, in patients with T2DM. Although it had a good safety profile in clinical trials, there may be some safety concerns, including a possible decrease in muscle mass and an increase in ketone bodies. Therefore, careful administration and consideration of its benefit-risk balance are necessary. When using luseogliflozin, it is important to select appropriate patients and to adhere to its guidelines for use. If used correctly, luseogliflozin is expected to be positioned as a new type of oral hypoglycemic drug for treating T2DM.
['Seino|Yutaka|Y|']
D001786:Blood Glucose D002986:Clinical Trials as Topic D003924:Diabetes Mellitus, Type 2 D004359:Drug Therapy, Combination D006207:Half-Life D006801:Humans D007004:Hypoglycemic Agents D051297:Sodium-Glucose Transporter 2 D000077203:Sodium-Glucose Transporter 2 Inhibitors D013012:Sorbitol
luseogliflozin sodium glucose cotransport type 2 diabetes mellitus sodium glucose cotransporter 2 inhibitor